Welcome to our dedicated page for Verastem SEC filings (Ticker: VSTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Verastem, Inc. filings document a Nasdaq-listed biopharmaceutical company with common stock trading under VSTM and a business focused on RAS/MAPK pathway-driven cancers. Its 8-K reports furnish corporate presentations, financial-result releases, strategic updates, clinical data disclosures, and Regulation FD materials for AVMAPKI FAKZYNJA CO-PACK, RAMP clinical programs, and VS-7375.
The company’s SEC records also cover capital-structure activity, including common stock and pre-funded warrant offerings, and proxy disclosures for board matters, executive compensation, equity awards, and shareholder voting. These filings frame Verastem’s commercialization, pipeline development, governance, financing, and public-company reporting obligations.
Stuglik Brian M reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc. director Brian M. Stuglik received an equity grant of 36,000 restricted stock units (RSUs) of Common Stock. The RSUs were granted at no cash cost as director compensation and will vest in twelve substantially equal monthly installments from late June 2026 through April 2027, with the final installment vesting on the earlier of the day before the 2027 Annual Meeting of Stockholders or May 31, 2027, subject to continued board service. Following this award, Stuglik holds 137,147 shares of Verastem Common Stock directly.
Rowinsky Eric K reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc. director Eric K. Rowinsky received a grant of 36,000 restricted stock units (RSUs). The grant was made at a price of $0.00 per share under Verastem’s Amended and Restated 2021 Equity Incentive Plan, reflecting stock-based compensation rather than an open-market purchase.
Each RSU represents the right to receive one share of common stock. The RSUs vest in twelve substantially equal monthly installments from the end of June 2026 through April 2027, with the final installment vesting on the earlier of the day before the 2027 annual stockholders’ meeting or May 31, 2027, contingent on his continued board service. Following this award, Rowinsky directly holds 52,666 shares of Verastem common stock.
ROBERTSON MICHELLE reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc. director Michelle Robertson received a grant of 36,000 restricted stock units (RSUs) of Common Stock as equity compensation. The award was granted at no cash cost per share and is structured to vest over time rather than all at once.
The RSUs were granted under Verastem's Amended and Restated 2021 Equity Incentive Plan, with each RSU representing the right to receive one share of Common Stock. The units vest in twelve substantially equal monthly installments from the end of June 2026 through April 2027, with the final installment vesting on the earlier of the day before the 2027 Annual Meeting of Stockholders or May 31, 2027, subject to her continued board service. After this grant, Robertson directly holds 52,666 shares of Verastem common stock.
Kapur Anil reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc. director Anil Kapur received a grant of 36,000 restricted stock units (RSUs). The award was made at no cash cost per share and increased his directly held common stock-related position to 52,666 shares as reported after the transaction.
The RSUs were granted under Verastem’s Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the right to receive one share of common stock, vesting in twelve substantially equal monthly installments from late June 2026 through April 2027, with the final installment vesting by May 31, 2027, if he continues serving as a director.
Bunn Paul A. reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc. director Paul A. Bunn received an equity grant of 36,000 shares of Common Stock in the form of restricted stock units (RSUs) under the company’s Amended and Restated 2021 Equity Incentive Plan. This is a compensation-related award, not an open-market purchase.
Each RSU represents one share of Common Stock. The award vests in twelve substantially equal monthly installments from the end of June 2026 through April 2027, with the final installment vesting on the earlier of the day before the 2027 annual stockholder meeting or May 31, 2027, subject to his continued board service. After this grant, Bunn holds 44,333 shares directly.
JOHNSON JOHN reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc. director John Johnson reported receiving a grant of 36,000 restricted stock units (RSUs) of Common Stock at no cash cost as equity compensation. Following this award, he holds 52,666 shares directly.
The RSUs were granted under Verastem's Amended and Restated 2021 Equity Incentive Plan. They vest in twelve substantially equal monthly installments from the end of June 2026 through April 2027, with the final installment vesting before the 2027 Annual Meeting of Stockholders or by May 31, 2027, as long as he continues serving as a director on each vesting date.
Verastem, Inc. reported the results of its 2026 annual stockholder meeting held in Needham, Massachusetts on May 21, 2026. Stockholders elected Class II directors Michael Bailey, Brian Stuglik and Karin Tollefson to serve until the 2029 annual meeting.
Investors also approved the Amended and Restated 2021 Equity Incentive Plan and the Amended and Restated 2018 Employee Stock Purchase Plan, supporting the company’s long-term compensation and employee ownership programs. Stockholders ratified Ernst & Young LLP as independent auditor for the current fiscal year and gave advisory approval to the compensation of the company’s named executive officers.
Foresite Capital Fund VI LP and related reporting persons report beneficial ownership of 3,146,631 shares of Verastem, Inc. common stock, representing 3.6% of the class. The percentage is calculated using 87,873,639 shares outstanding as of May 4, 2026, per the issuer's Form 10-Q.
The filing is an amendment to a Schedule 13G filed jointly by Foresite Capital Fund VI LP, Foresite Capital Management VI LLC and James B. Tananbaum and describes voting and dispositive power attributable through the fund and its general partner.
Verastem, Inc. Schedule 13G/A: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 4,592,000 shares of Verastem common stock, equal to 5.23% of the class as of 03/31/2026. The filing states Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd. (the Master Fund), shares voting and dispositive power over those shares; the Master Fund disclaims beneficial ownership by virtue of the Investment Management Agreement. The statement is a joint filing by Armistice Capital and Steven Boyd and lists shared voting and dispositive power of 4,592,000 shares.
Verastem, Inc. Schedule 13G/A amendment reporting that RTW Investments, LP and Roderick Wong each claim beneficial ownership of 9,018,724 shares of Common Stock, representing 9.99% of the class assuming exercise of Warrants. The filing states the percentage is calculated using 87,835,106 Shares outstanding as of February 27, 2026 and assumes exercise of 2,442,418 Warrants subject to a 9.99% ownership cap on exercise.
The filing explains shared voting and dispositive power over 9,018,724 Shares for both reporting persons, and notes RTW Funds hold the right to receive dividends or sale proceeds, with RTW Master Fund, Ltd. identified as holding over 5% of the reported shares. The statement is signed by Roderick Wong.